The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation

Yucheng Xiao, Kenneth Blumenthal, James O. Jackson, Songping Liang, Theodore Cummins

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The voltage-gated sodium channel Nav1.7 plays a crucial role in pain, and drugs that inhibit hNav1.7 may have tremendous therapeutic potential. ProTx-II and huwentoxin-IV (HWTX-IV), cystine knot peptides from tarantula venoms, preferentially block hNav1.7. Understanding the interactions of these toxins with sodium channels could aid the development of novel pain therapeutics. Whereas both ProTx-II and HWTX-IV have been proposed to preferentially block hNav1.7 activation by trapping the domain II voltage-sensor in the resting configuration, we show that specific residues in the voltage-sensor paddle of domain II play substantially different roles in determining the affinities of these toxins to hNav1.7. The mutation E818C increases ProTx-II's and HWTX-IV's IC50 for block of hNa v1.7 currents by 4- and 400-fold, respectively. In contrast, the mutation F813G decreases ProTx-II affinity by 9-fold but has no effect on HWTX-IV affinity. It is noteworthy that we also show that ProTx-II, but not HWTX-IV, preferentially interacts with hNav1.7 to impede fast inactivation by trapping the domain IV voltage-sensor in the resting configuration. Mutations E1589Q and T1590K in domain IV each decreased ProTx-II's IC50 for impairment of fast inactivation by ∼6-fold. In contrast mutations D1586A and F1592A in domain-IV increased ProTx-II's IC50 for impairment of fast inactivation by ∼4-fold. Our results show that whereas ProTx-II and HWTX-IV binding determinants on domain-II may overlap, domain II plays a much more crucial role for HWTX-IV, and contrary to what has been proposed to be a guiding principle of sodium channel pharmacology, molecules do not have to exclusively target the domain IV voltage-sensor to influence sodium channel inactivation.

Original languageEnglish
Pages (from-to)1124-1134
Number of pages11
JournalMolecular Pharmacology
Volume78
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Sodium Channels
Inhibitory Concentration 50
Mutation
NAV1.7 Voltage-Gated Sodium Channel
Spider Venoms
Pain
Cystine
huwentoxin II
Pharmacology
Peptides
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation. / Xiao, Yucheng; Blumenthal, Kenneth; Jackson, James O.; Liang, Songping; Cummins, Theodore.

In: Molecular Pharmacology, Vol. 78, No. 6, 12.2010, p. 1124-1134.

Research output: Contribution to journalArticle

@article{17e1cc83ed9d4c179e285043d8c03e0b,
title = "The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation",
abstract = "The voltage-gated sodium channel Nav1.7 plays a crucial role in pain, and drugs that inhibit hNav1.7 may have tremendous therapeutic potential. ProTx-II and huwentoxin-IV (HWTX-IV), cystine knot peptides from tarantula venoms, preferentially block hNav1.7. Understanding the interactions of these toxins with sodium channels could aid the development of novel pain therapeutics. Whereas both ProTx-II and HWTX-IV have been proposed to preferentially block hNav1.7 activation by trapping the domain II voltage-sensor in the resting configuration, we show that specific residues in the voltage-sensor paddle of domain II play substantially different roles in determining the affinities of these toxins to hNav1.7. The mutation E818C increases ProTx-II's and HWTX-IV's IC50 for block of hNa v1.7 currents by 4- and 400-fold, respectively. In contrast, the mutation F813G decreases ProTx-II affinity by 9-fold but has no effect on HWTX-IV affinity. It is noteworthy that we also show that ProTx-II, but not HWTX-IV, preferentially interacts with hNav1.7 to impede fast inactivation by trapping the domain IV voltage-sensor in the resting configuration. Mutations E1589Q and T1590K in domain IV each decreased ProTx-II's IC50 for impairment of fast inactivation by ∼6-fold. In contrast mutations D1586A and F1592A in domain-IV increased ProTx-II's IC50 for impairment of fast inactivation by ∼4-fold. Our results show that whereas ProTx-II and HWTX-IV binding determinants on domain-II may overlap, domain II plays a much more crucial role for HWTX-IV, and contrary to what has been proposed to be a guiding principle of sodium channel pharmacology, molecules do not have to exclusively target the domain IV voltage-sensor to influence sodium channel inactivation.",
author = "Yucheng Xiao and Kenneth Blumenthal and Jackson, {James O.} and Songping Liang and Theodore Cummins",
year = "2010",
month = "12",
doi = "10.1124/mol.110.066332",
language = "English",
volume = "78",
pages = "1124--1134",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation

AU - Xiao, Yucheng

AU - Blumenthal, Kenneth

AU - Jackson, James O.

AU - Liang, Songping

AU - Cummins, Theodore

PY - 2010/12

Y1 - 2010/12

N2 - The voltage-gated sodium channel Nav1.7 plays a crucial role in pain, and drugs that inhibit hNav1.7 may have tremendous therapeutic potential. ProTx-II and huwentoxin-IV (HWTX-IV), cystine knot peptides from tarantula venoms, preferentially block hNav1.7. Understanding the interactions of these toxins with sodium channels could aid the development of novel pain therapeutics. Whereas both ProTx-II and HWTX-IV have been proposed to preferentially block hNav1.7 activation by trapping the domain II voltage-sensor in the resting configuration, we show that specific residues in the voltage-sensor paddle of domain II play substantially different roles in determining the affinities of these toxins to hNav1.7. The mutation E818C increases ProTx-II's and HWTX-IV's IC50 for block of hNa v1.7 currents by 4- and 400-fold, respectively. In contrast, the mutation F813G decreases ProTx-II affinity by 9-fold but has no effect on HWTX-IV affinity. It is noteworthy that we also show that ProTx-II, but not HWTX-IV, preferentially interacts with hNav1.7 to impede fast inactivation by trapping the domain IV voltage-sensor in the resting configuration. Mutations E1589Q and T1590K in domain IV each decreased ProTx-II's IC50 for impairment of fast inactivation by ∼6-fold. In contrast mutations D1586A and F1592A in domain-IV increased ProTx-II's IC50 for impairment of fast inactivation by ∼4-fold. Our results show that whereas ProTx-II and HWTX-IV binding determinants on domain-II may overlap, domain II plays a much more crucial role for HWTX-IV, and contrary to what has been proposed to be a guiding principle of sodium channel pharmacology, molecules do not have to exclusively target the domain IV voltage-sensor to influence sodium channel inactivation.

AB - The voltage-gated sodium channel Nav1.7 plays a crucial role in pain, and drugs that inhibit hNav1.7 may have tremendous therapeutic potential. ProTx-II and huwentoxin-IV (HWTX-IV), cystine knot peptides from tarantula venoms, preferentially block hNav1.7. Understanding the interactions of these toxins with sodium channels could aid the development of novel pain therapeutics. Whereas both ProTx-II and HWTX-IV have been proposed to preferentially block hNav1.7 activation by trapping the domain II voltage-sensor in the resting configuration, we show that specific residues in the voltage-sensor paddle of domain II play substantially different roles in determining the affinities of these toxins to hNav1.7. The mutation E818C increases ProTx-II's and HWTX-IV's IC50 for block of hNa v1.7 currents by 4- and 400-fold, respectively. In contrast, the mutation F813G decreases ProTx-II affinity by 9-fold but has no effect on HWTX-IV affinity. It is noteworthy that we also show that ProTx-II, but not HWTX-IV, preferentially interacts with hNav1.7 to impede fast inactivation by trapping the domain IV voltage-sensor in the resting configuration. Mutations E1589Q and T1590K in domain IV each decreased ProTx-II's IC50 for impairment of fast inactivation by ∼6-fold. In contrast mutations D1586A and F1592A in domain-IV increased ProTx-II's IC50 for impairment of fast inactivation by ∼4-fold. Our results show that whereas ProTx-II and HWTX-IV binding determinants on domain-II may overlap, domain II plays a much more crucial role for HWTX-IV, and contrary to what has been proposed to be a guiding principle of sodium channel pharmacology, molecules do not have to exclusively target the domain IV voltage-sensor to influence sodium channel inactivation.

UR - http://www.scopus.com/inward/record.url?scp=78649959796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649959796&partnerID=8YFLogxK

U2 - 10.1124/mol.110.066332

DO - 10.1124/mol.110.066332

M3 - Article

C2 - 20855463

AN - SCOPUS:78649959796

VL - 78

SP - 1124

EP - 1134

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -